By 1970 the administration of aluminium hydroxide and/or calcium carbonate as phosphate binders in dialysis patients was virtually universal practice. In 1972, Alfrey was one of the first to ...

Hyperphosphatemia is linked to increased mortality risk. Dialysis patients often face a high daily pill burden, with phosphate binders making up about 50% of the total. Nonadherence to phosphate ...

Phosphate binders work by forming an insoluble phosphate ... hyperparathyroidism in CKD stages 3 and 4 CKD = chronic kidney disease. Cinacalcet is a calcimimetic indicated to treat secondary ...

Dialysis patients often face a high daily pill burden, with phosphate binders making up about 50% of the total. Nonadherence to phosphate binders is a significant challenge contributing to ...

In chronic kidney disease (CKD), the calcium–PTH–vitamin ... In addition, we discuss the effects of newer phosphate binders and calcium-receptor agonists on the future application of vitamin ...

The review draws attention to the high non-adherence rates to phosphate binders, which are crucial in managing hyperphosphatemia in dialysis patients. Non-adherence rates range from 22% to 74% ...

Background: Aluminium-containing phosphate binders have long been used for treatment of hyperphosphatemia in dialysis patients. Their safety became controversial in the early 1980's after reports ...

Hyperphosphatemia is linked to increased mortality risk. Dialysis patients often face a high daily pill burden, with phosphate binders making up about 50% of the total. Nonadherence to phosphate ...

Engaging patients in discussions about different phosphate binders and their unique characteristics is key to improving adherence and satisfaction. New therapies that reduce pill size or burden while ...